← Back

Disc Medicine Inc.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes novel treatments for serious hematologic diseases in the United States. Its portfolio of clinical and preclinical candidates targets fundamental biological pathways related to red blood cell formation and function, primarily heme biosynthesis and iron homeostasis. The pipeline includes bitopertin for erythropoietic porphyrias (including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia), DISC-0974 for anemia of myelofibrosis and anemia of chronic kidney disease, and DISC-3405 for polycythemia vera and other hematologic disorders. Preclinical programs include DISC-0998 for anemia associated with inflammatory diseases. Founded in 2017, the company is headquartered in Watertown, Massachusetts.

Country
Price · split & dividend adjusted
News & notes moving IRON
IRON▲

Disc Medicine posts Q2 GAAP EPS of -$1.54, beating estimates by $0.19

Disc Medicine reported second-quarter 2026 GAAP earnings per share of -$1.54, surpassing consensus estimates by $0.19. The company ended the quarter with approximately $718 million in cash, cash equivalents, and marketable securities, which it expects will fund operations into 2029.
IRON ▲
IRON · Capital · Positive Q2 GAAP EPS beat estimates by $0.19 and cash runway extended into 2029
Read original ↗
Seeking Alpha·67dRead more →
IRON▼2

Rosen Law Firm Investigates Disc Medicine Over Potential Securities Claims

The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. following allegations that the company may have issued materially misleading business information. The investigation stems from a February 13, 2026 Complete Response Letter from the U.S. Food and Drug Administration regarding Disc Medicine's bitopertin program, which stated the new drug application could not be approved due to uncertainties requiring additional evidence. On that news, Disc Medicine's stock price fell 22%. The law firm is preparing a class action seeking recovery of investor losses on a contingency fee basis.
IRON ▼
IRON · Regulation · Negative FDA Complete Response Letter rejecting bitopertin NDA due to uncertainties, causing 22% stock drop and securities investigation.
Read original ↗
GlobeNewswire·68dRead more →
IRON▼6

Rosen Law Firm investigates Disc Medicine over potential securities claims

The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders, alleging the company may have issued materially misleading business information. The investigation follows a February 13, 2026 Complete Response Letter from the FDA regarding Disc Medicine’s bitopertin program, which stated the new drug application could not be approved due to uncertainties requiring additional evidence. On that news, Disc Medicine’s stock price fell 22%. The law firm is preparing a class action seeking recovery of investor losses on a contingency fee basis.
IRON ▼
IRON · Regulation · Negative FDA Complete Response Letter rejecting bitopertin NDA due to uncertainties
Read original ↗
GlobeNewswire·81dRead more →
IRON▼3

Rosen Law Firm Investigates Disc Medicine Over Potential Securities Claims

The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. following allegations that the company may have issued materially misleading business information. The investigation stems from a February 13, 2026 announcement that the U.S. Food and Drug Administration issued a Complete Response Letter regarding Disc Medicine's bitopertin program, stating it could not approve the new drug application due to uncertainties requiring additional evidence. On that news, Disc Medicine's stock price fell 22%. The Rosen Law Firm is preparing a class action seeking recovery of investor losses and encourages affected shareholders to contact the firm.
IRON ▼
IRON · Regulation · Negative FDA issued Complete Response Letter rejecting bitopertin, causing 22% stock drop and securities investigation.
Read original ↗
GlobeNewswire·88dRead more →
© 2026 MarketDXAsset